News

Video

T-DXd in HER2 Mutated Advanced NSCLC

Author(s):

Shirish Gadgeel, MD,Benjamin Levy, MD

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Current Time 0:00
Duration 10:38
Loaded: 0%
Stream Type LIVE
Remaining Time 10:38
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
Related Videos
2 experts in this video
Key Updates in the Treatment of ES-SCLC
2 experts in this video
Expert Insights on Recent Advancements in LS-SCLC
2 expert is featured in this series.
Logistical Considerations for Delivering TCR Therapy to Patients
2 expert is featured in this series.
Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens
SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC
SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC
2 experts are featured in this series.
Key Takeaways and Future Perspectives for In-House Biomarker Testing
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
2 expert is featured in this series.
Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases
2 expert is featured in this series.
Approaches to First-Line Treatment for Synovial Sarcoma
2 experts are featured in this series.
Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity
Related Content
FDA priority review for zongertinib in HER2-mutant NSCLC
February 19th 2025

FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

US FDA
February 17th 2025

FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Resectable NSCLC | Image Credit: © catalin - stock.adobe.com
February 11th 2025

Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.
February 9th 2025

Five Under 5: Top Oncology Videos for the Week of 2/2